Literature DB >> 15994792

The replicative fitness of primary human immunodeficiency virus type 1 (HIV-1) group M, HIV-1 group O, and HIV-2 isolates.

Kevin K Ariën1, Awet Abraha, Miguel E Quiñones-Mateu, Luc Kestens, Guido Vanham, Eric J Arts.   

Abstract

The main (M) group of human immunodeficiency virus type 1 (HIV-1) is responsible for the global AIDS epidemic while HIV-1 group O (outlier) and HIV type 2 are endemic only in west and central Africa. The failure of HIV-2 and especially HIV-1 group O to spread following the initial zoonotic jumps is not well understood. This study was designed to examine the relative replicative capacities between these human lentiviruses. A pairwise competition experiment was performed with peripheral blood mononuclear cells with eight HIV-2 isolates, 6 group O viruses, and 15 group M viruses of subtype A (2 viruses), B (5 viruses), C (4 viruses), D (2 viruses) and CRF01_AE (2 viruses). HIV-1 group M isolates of any subtype were typically 100-fold-more fit than group O or HIV-2 strains when competed in peripheral blood mononuclear cells from various humans. This order in replicative fitness was also observed when virus pairs were added to human dendritic cells and then cocultured with primary, quiescent T cells, which is the model for HIV-1 transmission. These results suggest that reduced replicative and transmission fitness may be contributing to the low prevalence and limited geographical spread of HIV-2 and group O HIV-1 in the human population.

Entities:  

Mesh:

Year:  2005        PMID: 15994792      PMCID: PMC1168791          DOI: 10.1128/JVI.79.14.8979-8990.2005

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  56 in total

1.  In vivo HIV-1 infection of CD45RA(+)CD4(+) T cells is established primarily by syncytium-inducing variants and correlates with the rate of CD4(+) T cell decline.

Authors:  H Blaak; A B van't Wout; M Brouwer; B Hooibrink; E Hovenkamp; H Schuitemaker
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-01       Impact factor: 11.205

2.  Exponential increases of RNA virus fitness during large population transmissions.

Authors:  I S Novella; E A Duarte; S F Elena; A Moya; E Domingo; J J Holland
Journal:  Proc Natl Acad Sci U S A       Date:  1995-06-20       Impact factor: 11.205

3.  Variable sensitivity of CCR5-tropic human immunodeficiency virus type 1 isolates to inhibition by RANTES analogs.

Authors:  V S Torre; A J Marozsan; J L Albright; K R Collins; O Hartley; R E Offord; M E Quiñones-Mateu; E J Arts
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

4.  HIV-infected human Langerhans cells transmit infection to human lymphoid tissue ex vivo.

Authors:  A Blauvelt; S Glushakova; L B Margolis
Journal:  AIDS       Date:  2000-04-14       Impact factor: 4.177

Review 5.  Short-sighted evolution and the virulence of pathogenic microorganisms.

Authors:  B R Levin; J J Bull
Journal:  Trends Microbiol       Date:  1994-03       Impact factor: 17.079

6.  CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice.

Authors:  J D Thompson; D G Higgins; T J Gibson
Journal:  Nucleic Acids Res       Date:  1994-11-11       Impact factor: 16.971

7.  Size of genetic bottlenecks leading to virus fitness loss is determined by mean initial population fitness.

Authors:  I S Novella; S F Elena; A Moya; E Domingo; J J Holland
Journal:  J Virol       Date:  1995-05       Impact factor: 5.103

8.  Mapping the determinants of human immunodeficiency virus 2 for infectivity, replication efficiency, and cytopathicity.

Authors:  R Talbott; G Kraus; D Looney; F Wong-Staal
Journal:  Proc Natl Acad Sci U S A       Date:  1993-05-01       Impact factor: 11.205

9.  Reduced rate of disease development after HIV-2 infection as compared to HIV-1.

Authors:  R Marlink; P Kanki; I Thior; K Travers; G Eisen; T Siby; I Traore; C C Hsieh; M C Dia; E H Gueye
Journal:  Science       Date:  1994-09-09       Impact factor: 47.728

10.  Slower heterosexual spread of HIV-2 than HIV-1.

Authors:  P J Kanki; K U Travers; S MBoup; C C Hsieh; R G Marlink; A Gueye-NDiaye; T Siby; I Thior; M Hernandez-Avila; J L Sankalé
Journal:  Lancet       Date:  1994-04-16       Impact factor: 79.321

View more
  96 in total

1.  HIV-1 Group O Genotypes and Phenotypes: Relationship to Fitness and Susceptibility to Antiretroviral Drugs.

Authors:  Denis M Tebit; Hamish Patel; Annette Ratcliff; Elodie Alessandri; Joseph Liu; Crystal Carpenter; Jean-Christophe Plantier; Eric J Arts
Journal:  AIDS Res Hum Retroviruses       Date:  2016-03-16       Impact factor: 2.205

2.  Association between peripheral γδ T-cell profile and disease progression in individuals infected with HIV-1 or HIV-2 in West Africa.

Authors:  Natalie N Zheng; M Juliana McElrath; Papa Salif Sow; Andrew Mesher; Stephen E Hawes; Joshua Stern; Geoffrey S Gottlieb; Stephen C De Rosa; Nancy B Kiviat
Journal:  J Acquir Immune Defic Syndr       Date:  2011-06-01       Impact factor: 3.731

3.  Evaluation of a multiple-cycle, recombinant virus, growth competition assay that uses flow cytometry to measure replication efficiency of human immunodeficiency virus type 1 in cell culture.

Authors:  Carrie Dykes; Jiong Wang; Xia Jin; Vicente Planelles; Dong Sung An; Amanda Tallo; Yangxin Huang; Hulin Wu; Lisa M Demeter
Journal:  J Clin Microbiol       Date:  2006-06       Impact factor: 5.948

4.  Broad-spectrum anti-human immunodeficiency virus (HIV) potential of a peptide HIV type 1 entry inhibitor.

Authors:  Simon Cocklin; Hosahudya Gopi; Bianca Querido; Manideepthi Nimmagadda; Syna Kuriakose; Claudia Cicala; Sandya Ajith; Sabine Baxter; James Arthos; Julio Martín-García; Irwin M Chaiken
Journal:  J Virol       Date:  2007-01-24       Impact factor: 5.103

5.  A Multiplex PCR Approach for Detecting Dual Infections and Recombinants Involving Major HIV Variants.

Authors:  Pierre Cappy; Fabienne De Oliveira; Marie Gueudin; Elodie Alessandri-Gradt; Jean-Christophe Plantier
Journal:  J Clin Microbiol       Date:  2016-02-24       Impact factor: 5.948

6.  Cellular microRNA and P bodies modulate host-HIV-1 interactions.

Authors:  Robin Nathans; Chia-Ying Chu; Anna Kristina Serquina; Chih-Chung Lu; Hong Cao; Tariq M Rana
Journal:  Mol Cell       Date:  2009-06-26       Impact factor: 17.970

7.  Access of HIV-2 to CD169-dependent dendritic cell-mediated trans infection pathway is attenuated.

Authors:  Suzanne D G Kijewski; Hisashi Akiyama; Amin Feizpour; Caitlin M Miller; Nora-Guadalupe P Ramirez; Björn M Reinhard; Suryaram Gummuluru
Journal:  Virology       Date:  2016-08-11       Impact factor: 3.616

8.  CCR5- and CXCR4-tropic subtype C human immunodeficiency virus type 1 isolates have a lower level of pathogenic fitness than other dominant group M subtypes: implications for the epidemic.

Authors:  Awet Abraha; Immaculate L Nankya; Richard Gibson; Korey Demers; Denis M Tebit; Elizabeth Johnston; David Katzenstein; Asna Siddiqui; Carolina Herrera; Lucia Fischetti; Robin J Shattock; Eric J Arts
Journal:  J Virol       Date:  2009-03-18       Impact factor: 5.103

9.  Emergence of multiclass drug-resistance in HIV-2 in antiretroviral-treated individuals in Senegal: implications for HIV-2 treatment in resouce-limited West Africa.

Authors:  Geoffrey S Gottlieb; Ndeye Mery Dia Badiane; Stephen E Hawes; Louise Fortes; Macoumba Toure; Cheikh T Ndour; Alison K Starling; Fatou Traore; Fatima Sall; Kim G Wong; Stephen L Cherne; Donovan J Anderson; Stefanie A Dye; Robert A Smith; James I Mullins; Nancy B Kiviat; Papa Salif Sow
Journal:  Clin Infect Dis       Date:  2009-02-15       Impact factor: 9.079

10.  Modulation of the severe CD4+ T-cell loss caused by a pathogenic simian-human immunodeficiency virus by replacement of the subtype B vpu with the vpu from a subtype C HIV-1 clinical isolate.

Authors:  M Sarah Hill; Autumn Ruiz; Erik Pacyniak; David M Pinson; Nathan Culley; Bonnie Yen; Scott W Wong; Edward B Stephens
Journal:  Virology       Date:  2007-10-24       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.